BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
Study sponsor: BioCryst Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-18Actual
Enrollment · participants12Actual
Source updated2026-10-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.